Investor Days Thuringia 2021
On June 15 and 16, 2021, the Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT) and bm-t beteiligungsmanagement thüringen gmbh (bm|t) organized the “Investor Days Thuringia” (IDT) in Erfurt – in digital format due to the corona pandemic.
We were happy that Dynamic42 received one of the coveted lecture places. A total of 23 start-ups and 13 growth companies presented their business concepts on the digital IDT pitch stage on 15 June. Ahead 67 projects from Germany, Austria, Israel, Italy, New Zealand, Spain, South Africa, the Czech Republic, Hungary, and Uruguay applied.
Our managing directors Dr. Martin Raasch and Dr. Knut Rennert presented Dynamic42 GmbH in a five-minute pitch in the category “Growth Companies”. In addition to the Dynamic42 organ-on-chip models and current market figures, Knut and Martin talked about the company’s goals and outlined the strategic positioning of the coming years.
On June 15, we were also represented with our digital booth in the Innovation Arena. Here we were able to establish further contacts with investors and multipliers and initiate the first potential cooperation.
On the second day, we were able to intensively exchange and network with representatives of the local economy, start-up scene and contact persons for funding instruments in a round-table format.
We would like to thank the organizers of the “Investor Days” for the successful event. This event has brought us plenty positive feedback and make new contacts with investors possible.
About the Investor Days Thuringia 2021
From June 15 to 16, innovation-driven start-ups and growth companies met with national and international industries and investors. As part of this online event, around 600 participants exchanged their view on latest technologies and trends from various industries. The whole program was broadcast live from the Erfurt Multifunctional Arena.
Picture: Mobile Event App
More interesting articles:
Blog
Will organ-on-chip replace animal testing?
Will advanced in vitro models such as organ-on-chip replace animal testing? An opinion piece by our CEO and co-foudner Dr. Martin Raasch.
Read MoreBlog
The PDAC-on-Chip – A New Dimension in Pancreatic Cancer Research
A new biochip replicates key aspects of the PDAC microenvironment, providing a powerful tool for drug development and reduction of animal testing.
Read MoreBlog
What is TEER? – Trans-Epithelial Electrical Resistance Assay
Here we explore TEER assays as an excellent method to determine barrier, and thereby epithelial and endothelial tissue integrity.
Read More